APP-based Precise Management System of Chronic Intractable Pain

Pain, Chronic Clinical Trial

— PreMaSy  

Official title:

Precise Management System (PreMaSy) of Chronic Intractable Pain Based on a Remote and Wireless Spinal Cord Stimulation System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05761392
• Other study ID #: 20220908
• Status: Recruiting
• Phase: N/A
• Start date: September 26, 2022
• Est. completion date: September 25, 2026

Study information

• Verified date: March 2023
• Source: Beijing Tsinghua Chang Gung Hospital
• Contact: Yang Lu, MD
• Phone: 18600391166
• Email: lya02121[@]btch.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about a new management system in chronic and stubborn pain patients who accept therapy of spinal cord stimulation (SCS). Usually, these patients are required to take long-term follow-ups to ensure that the stimulator works well. The main questions it aims to answer are:

• Is it better to improve the patient's quality of life than the current conventional follow-up?

• Is it better to relieve pain in the long term than the current conventional follow-up?

• Is it possible to be applied to a large population of chronic pain patients? Participants will be randomly assigned to either a control group or an interventional group.

Participants in the control group will be given the standard SCS implantation surgery and asked to complete the conventional follow-up (at least 1-, 3-, and 6-month post-operative).

Participants in the interventional group will be given the standard SCS implantation surgery and asked to do the following things:

• Take the daily pain self-assessment questions on a mobile phone APP.

• Take the monthly healthy status self-assessment questionnaires on a mobile phone APP.

• Take the conventional follow-up (at least 1-, 3-, and 6-month post-operative). Researchers will compare the two groups to see if the life quality of the interventional group is improved.

Description:

Chronic intractable pain is a disorder with complicated causes. The patient's quality of life is significantly reduced as a result of the patient's ongoing discomfort and the necessity for lengthy therapies. When patients don't respond well to medicine or other non-surgical treatments, spinal cord stimulation (SCS) is one of the surgical methods employed. The safety and effectiveness of SCS have previously been confirmed in numerous trials as a well-researched and clinically used therapy. However, the adjustment of SCS is complicated and its optimal effect relies on long-term regular follow-up. With the development of the internet, the investigators put forward a new system with remote and wireless SCS devices. Together with an exclusively developed mobile phone application, patients will be able to record their daily pain state and monthly health condition and make customized stimulation settings accordingly. This study is aimed to test the feasibility of this new precise management system. All participants will be randomly assigned to either interventional or control group. Participants in control group will be asked to take the conventional follow-up. Participants in interventional group will be additionally asked to take self-assessment on daily pain state and monthly health condition. The investigators hypothesized that this self-involved, closely monitored, and precisely adjusted system can significantly improve patients' quality of life in the long term and cut down both the financial expenses and time cost.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: September 25, 2026
• Est. primary completion date: September 25, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have been clinically diagnosed with chronic, intractable pain for more than three months.

• At enrollment, the average pain intensity is no least than 5 out of 10 cm on visual analogue scale.

• At enrollment, the age is no younger than 18-year-old.

• Ineffective or unsatisfactory conservative treatments, including but limited to: oral medication, nerve block, epidural corticosteroids, physical and psychological rehabilitation therapy, and chiropractic care.

• Voluntary to take the trial and sign the informed consent.

• Good compliance and ability to complete post-operative follow-ups.

• Basic ability to read and use a mobile phone or having a caregiver who can.

Exclusion Criteria:

• Bleeding complications or coagulation disorders.

• Mental or cognitive disorders leading to inability to complete implantation surgery or post-operative follow-up.

• Issues with spinal cord or vertebrates that are not suitable for implantation surgery.

• Systemic active infections or local infections around the surgery area.

• Pregnancy, breast-feeding, plan to be pregnant or unwilling to use contraceptive methods.

• Metastatic malignant tumors or untreated malignant tumors.

• Life expectancy of less than one year.

• Already provided with a medication pump and/or other implanted devices.

• Need for therapy or examination that must not have an implanted pulse generator (IPG), such as magnetic resonance imaging (MRI) and thermo-therapy.

• Heavily addicted to alcohol or drugs.

• VAS improvement less than 50% or stimulation intolerance during the test period.

• Unable to complete long-term online follow-ups because of hardware issues such as internet, mobile phones, and so on.

• Unwilling to participate.

• Other inappropriate situations determined by the investigators.

Related Conditions & MeSH terms

• Chronic Pain
• Pain, Chronic
• Pain, Intractable

Intervention

Other:
• Precise management
The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.

Locations

Country	Name	City	State
China	Beijing Tsinghua Chang Gung Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Tsinghua Chang Gung Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Han Y, Lu Y, Wang D, Ran M, Ren Q, Xie D, Aziz TZ, Li L, Wang JJ. The Use of Remote Programming for Spinal Cord Stimulation for Patients With Chronic Pain During the COVID-19 Outbreak in China. Neuromodulation. 2021 Apr;24(3):441-447. doi: 10.1111/ner.13382. Epub 2021 Mar 22. — View Citation

Lu Y, Xie D, Zhang X, Dong S, Zhang H, Yu B, Wang G, Wang JJ, Li L. Management of Intractable Pain in Patients With Implanted Spinal Cord Stimulation Devices During the COVID-19 Pandemic Using a Remote and Wireless Programming System. Front Neurosci. 2020 Dec 8;14:594696. doi: 10.3389/fnins.2020.594696. eCollection 2020. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 1	Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.	Baseline and Month 1
Primary	Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 3	Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.	Baseline and Month 3
Primary	Health Condition and Life Quality: Change From Baseline in five-level EuroQol five-dimensional questionnaire (EQ-5D-5L) utility values at Month 6	Participants' health condition and life quality are measured by EQ-5D-5L utility values. EQ-5D-5L utility value has a minimum of 0 and a maximum of 1. Higher values mean a better health condition.	Baseline and Month 6
Secondary	Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 1	Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.	Baseline and Month 1
Secondary	Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 3	Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.	Baseline and Month 3
Secondary	Pain Intensity: Change From Baseline in Visual Analogue Scale (VAS) at Month 6	Pain intensity is assessed by VAS and compared with baseline VAS score. VAS has a minimum of 0 and a maximum of 10. Higher values mean a stronger pain.	Baseline and Month 6
Secondary	Pain Time: Change From Baseline in Time-Intensity Curve at Month 1	Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.	Baseline and Month 1
Secondary	Pain Time: Change From Baseline in Time-Intensity Curve at Month 3	Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.	Baseline and Month 3
Secondary	Pain Time: Change From Baseline in Time-Intensity Curve at Month 6	Temporal characteristics of pain is assessed by a time-intensity curve and compared with baseline curve.	Baseline and Month 6
Secondary	Pain Location: Change From Baseline in Pain Map at Month 1	Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.	Baseline and Month 1
Secondary	Pain Location: Change From Baseline in Pain Map at Month 3	Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.	Baseline and Month 3
Secondary	Pain Location: Change From Baseline in Pain Map at Month 6	Spatial characteristics of pain is assessed by a pain map and compared with baseline pain map.	Baseline and Month 6
Secondary	Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 1	Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.	Baseline and Month 1
Secondary	Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 3	Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.	Baseline and Month 3
Secondary	Health condition: Change From Baseline in EuroQol Visual Analogue Scale (EQ VAS) at Month 6	Overall health condition is assessed by EQ VAS and compared with baseline EQ VAS. EQ VAS has a minimum of 0 and a maximum of 100. Higher scores mean a better health condition.	Baseline and Month 6
Secondary	Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 1	Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.	Baseline and Month 1
Secondary	Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 3	Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.	Baseline and Month 3
Secondary	Sleep Quality: Change From Baseline in Pittsburgh Sleep Quality Index (PSQI) at Month 6	Sleep quality is assessed by PSQI and compared with baseline PSQI score. PSQI score has a minimum of 0 and maximum of 21. Higher scores mean a worse sleep quality.	Baseline and Month 6
Secondary	Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 1	The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 1
Secondary	Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 3	The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 3
Secondary	Global impression: Change From Baseline in Patient's Global Impression of Change (PGIC) at Month 6	The change of overall health condition is assessed by PGIC and compared with baseline PGIC score. PGIC score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 6
Secondary	Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 1	The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 1
Secondary	Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 3	The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 3
Secondary	Global impression: Change From Baseline in Clinical Global Impressions-Improvement (CGI-I) at Month 6	The change of overall health condition is assessed by physicians using the CGI-I and compared with baseline CGI-I score. CGI-I score has a minimum of 1 and a maximum of 7. Higher scores mean a greater improvement in health condition.	Baseline and Month 6